Eyepoint Pharmaceuticals (NASDAQ:EYPT) Rating Lowered to “Neutral” at Guggenheim

Eyepoint Pharmaceuticals (NASDAQ:EYPT) was downgraded by equities research analysts at Guggenheim from a “buy” rating to a “neutral” rating in a research report issued to clients and investors on Monday, MarketBeat Ratings reports.

Other research analysts have also issued research reports about the company. Weiss Ratings upgraded Eyepoint Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, September 1st. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Eyepoint Pharmaceuticals in a research report on Monday, August 17th. HC Wainwright reiterated a “neutral” rating on shares of Eyepoint Pharmaceuticals in a research note on Tuesday, August 18th. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $5.00 price objective on shares of Eyepoint Pharmaceuticals in a research note on Tuesday, August 18th. Finally, Jefferies Financial Group lowered Eyepoint Pharmaceuticals from a “buy” rating to a “hold” rating and set a $1.00 price objective for the company. in a research note on Monday. Two investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $25.00.

Eyepoint Pharmaceuticals Stock Performance

Shares of Eyepoint Pharmaceuticals stock traded down $2.57 on Monday, reaching $0.42. 148,507,518 shares of the stock were exchanged, compared to its average volume of 2,867,290. The firm’s 50 day moving average is $5.02 and its 200-day moving average is $10.39. The firm has a market cap of $36.21 million, a PE ratio of -0.11 and a beta of 1.67. Eyepoint Pharmaceuticals has a one year low of $0.40 and a one year high of $19.11.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.08). The firm had revenue of $0.51 million for the quarter, compared to the consensus estimate of $0.45 million. Eyepoint Pharmaceuticals had a negative return on equity of 135.81% and a negative net margin of 10,994.73%. On average, equities research analysts expect that Eyepoint Pharmaceuticals will post -3.51 EPS for the current fiscal year.

Institutional Investors Weigh In On Eyepoint Pharmaceuticals

A number of large investors have recently made changes to their positions in EYPT. KBC Group NV bought a new position in Eyepoint Pharmaceuticals in the 1st quarter worth $29,000. Integrated Wealth Concepts LLC bought a new position in shares of Eyepoint Pharmaceuticals during the 2nd quarter valued at approximately $72,000. Pictet Asset Management Holding SA purchased a new stake in shares of Eyepoint Pharmaceuticals in the first quarter valued at $141,000. Engineers Gate Manager LP bought a new stake in Eyepoint Pharmaceuticals in the second quarter worth about $161,000. Finally, Janney Montgomery Scott LLC boosted its holdings in Eyepoint Pharmaceuticals by 14.8% during the 1st quarter. Janney Montgomery Scott LLC now owns 30,315 shares of the company’s stock valued at $391,000 after acquiring an additional 3,900 shares during the period. 99.41% of the stock is currently owned by institutional investors.

Eyepoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for serious eye diseases. The company specializes in sustained-release drug delivery technologies designed to provide extended treatment in the eye and potentially reduce the frequency of injections or other interventions.

EyePoint’s commercial products include YUTIQ, an intravitreal implant that delivers fluocinolone acetonide for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, an intraocular suspension of dexamethasone used to treat postoperative inflammation following ocular surgery.